docetaxel anhydrous has been researched along with Myelodysplastic Syndromes in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavez-MacGregor, M; Giordano, SH; Niu, J; Rosenstock, AS; Wolff, AC; Zhao, H | 1 |
| Arslan, C; Uslu, R | 1 |
| Griesinger, F; Haase, D; Metz, M; Schulz, T; Trümper, L | 1 |
| Fujimi, A; Kato, J; Kuribayashi, K; Matsunaga, T; Murase, K; Niitsu, Y; Sakai, T; Sasaki, A; Satoh, M; Takimoto, R; Tateno, K; Terui, T; Wada, Y | 1 |
4 other study(ies) available for docetaxel anhydrous and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Topics: Acute Disease; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Leukemia, Myeloid; Medicare; Myelodysplastic Syndromes; Neoplasm Staging; Registries; Risk Factors; SEER Program; Taxoids; Texas; United States | 2018 |
Secondary haematological malignancies in the BCIRG 001 study.
Topics: Cyclophosphamide; Docetaxel; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Taxoids | 2013 |
Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB.
Topics: Acute Disease; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Docetaxel; Humans; Karyotyping; Leukemia, Myeloid; Lung Neoplasms; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Taxoids | 2004 |
A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer.
Topics: Aged; Alleles; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Carboplatin; Codon; DNA; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, p53; Germ-Line Mutation; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Mutation, Missense; Myelodysplastic Syndromes; Ovarian Neoplasms; Ovariectomy; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Skin; Taxoids | 2005 |